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Background
MGA271 is a humanized IgG1 monoclonal antibody-
targeting B7-H3 (CD276), a member of the B7 family.
MGA271 has been Fc-engineered to enhance binding to
activating FcgR (CD16A), decrease binding to inhibitory
FcgR (CD32B), and potentiate ADCC. B7-H3 has limited
expression in normal tissues but highly expressed in a
broad range of tumors, making it an attractive target for
cancer immunotherapy. We initiated a Phase I investiga-
tion of the safety, tolerability, pharmacokinetics, phar-
macodynamics and antitumor activity of MGA271.
Methods
This Phase I study included dose escalation (complete)
and an ongoing two-component cohort expansion
(NCT01391143). Dose escalation utilized single-patient,
intra-patient escalation, followed by a conventional 3+3
design, using MGA271 doses of 0.01-15mg/kg. MGA271
was administered weekly on a 4-week on, 4-week off
schedule during cycle 1, and 3 out of every 4 weeks in
subsequent cycles. Initial expansion cohorts enrolled
patients (N=15/cohort) with melanoma, prostate carci-
noma and other B7-H3+ tumors. Major modifications
were subsequently made to enhance the functionality of
the study prior to enrolling additional expansion cohorts.
MGA271 administration was changed to uninterrupted
weekly dosing, corticosteroid infusion reaction prophy-
laxis was reduced and immune-related response criteria
and management principles were implemented. The
additional expansion cohorts (N=16/cohort) were
initiated in patients with melanoma (post checkpoint
inhibitor), squamous cell head and neck carcinoma, renal
cell carcinoma, triple-negative breast carcinoma, and
high-B7-H3 expressing tumors including bladder and
lung carcinoma. Pharmacodynamic testing included
serum cytokines and modulation of the lymphocyte phe-
notype and T cell repertoire in peripheral blood.
Results
MGA271 was well tolerated, with no dose-limiting toxicity
and no maximum tolerated dose defined up to 15 mg/kg.
Patients were frequently heavily pre-treated, with a median
of 3 (0-7) prior therapies. Any grade treatment-related AEs
occurred in 71% of patients, including fatigue (30%), infu-
sion-related reaction (26%), nausea (19%), chills (17%) and
vomiting (13%). Grade 3/4 drug related AEs were noted in
6% of patients. No drug-related AEs led to study drug dis-
continuation. MGA271 showed linear PK. As of 30 July
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2015, 20 of 46 patients treated under the new study design
continue on study drug. Patients experienced disease stabi-
lization (>12 weeks) and tumor shrinkage (2-69%) across
several tumor types. The study continues to enroll patients
and generate more mature data.
Conclusions
MGA271 has a favorable safety profile and initial evidence
of anti-tumor activity across several tumor types. These
data support continued evaluation of MGA271 monother-
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